Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo-Lorduy A, Jimenez B, Muriel A, Mate JL, Moran T, Aranda I, Massuti B, Rojo F, Domine M, Sansano I, Garcia F, Felip E, Mancheño N, Juan O, Sanz J, Gonzalez-Larriba JL, Atienza-Cuevas L, Arriola-Arellano E, Abdulkader I, Garcia-Gonzalez J, Camacho C, Rodriguez-Abreu D, Teixido C, Reguart N, Gonzalez-Piñeiro A, Lazaro-Quintela M, Lozano MD, Gurpide A, Gomez-Roman J, Lopez-Brea M, Pijuan L, Salido M, Arriola E, Company A, Insa A, Esteban-Rodriguez I, Saiz M, Azkona E, Alvarez R, Artal A, Plaza ML, Aguiar D, Enguita AB, Benito A, Paz-Ares L, Garrido P, Lopez-Rios F.

J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562-3. doi: 10.1016/j.jtho.2019.07.005. [Epub ahead of print]

2.

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, Hechtman JF, Troiani T, López-Rios F, Douillard JY, Andrè F, Reis-Filho JS.

Ann Oncol. 2019 Jul 3. pii: mdz204. doi: 10.1093/annonc/mdz204. [Epub ahead of print]

PMID:
31268127
3.

Could WNT inhibitors really knock on the treatment door of small cell lung cancer?

Esteller L, Hernández S, Lopez-Rios F, Remon J.

J Thorac Dis. 2019 Mar;11(Suppl 3):S381-S384. doi: 10.21037/jtd.2018.12.46. No abstract available.

4.

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.

Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, Banna GL, De Giorgi U, Masini C, Bamias A, Garcia Del Muro X, Duran I, Powles T, Gamulin M, Zengerling F, Geczi L, Gedye C, de Ducla S, Fear S, Merseburger AS.

Eur Urol. 2019 Jul;76(1):73-81. doi: 10.1016/j.eururo.2019.03.015. Epub 2019 Mar 23.

5.

Implementing TMB measurement in clinical practice: considerations on assay requirements.

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F.

ESMO Open. 2019 Jan 24;4(1):e000442. doi: 10.1136/esmoopen-2018-000442. eCollection 2019.

6.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.

Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, Beasley MB, Thunnissen E, Pelosi G, Rekhtman N, Bubendorf L, Mino-Kenudson M, Yoshida A, Geisinger KR, Noguchi M, Chirieac LR, Bolting J, Chung JH, Chou TY, Chen G, Poleri C, Lopez-Rios F, Papotti M, Sholl LM, Roden AC, Travis WD, Hirsch FR, Kerr KM, Tsao MS, Nicholson AG, Wistuba I, Moreira AL.

J Thorac Oncol. 2019 Mar;14(3):377-407. doi: 10.1016/j.jtho.2018.12.005. Epub 2018 Dec 18.

PMID:
30572031
7.

ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat?

Cabillic F, Hofman P, Ilie M, Peled N, Hochmair M, Dietel M, Von Laffert M, Gosney JR, Lopez-Rios F, Erb G, Schalles U, Barlesi F.

ESMO Open. 2018 Sep 17;3(6):e000419. doi: 10.1136/esmoopen-2018-000419. eCollection 2018.

8.

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe.

Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC.

J Mol Diagn. 2018 Jul;20(4):483-494. doi: 10.1016/j.jmoldx.2018.03.006. Epub 2018 Apr 26.

PMID:
29704571
9.

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.

Díaz-Serrano A, Angulo B, Dominguez C, Pazo-Cid R, Salud A, Jiménez-Fonseca P, Leon A, Galan MC, Alsina M, Rivera F, Plaza JC, Paz-Ares L, Lopez-Rios F, Gómez-Martín C.

Oncologist. 2018 Sep;23(9):1092-1102. doi: 10.1634/theoncologist.2017-0379. Epub 2018 Apr 26.

PMID:
29700210
10.

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.

Garrido P, Olmedo ME, Gómez A, Paz Ares L, López-Ríos F, Rosa-Rosa JM, Palacios J.

Ther Adv Med Oncol. 2017 Sep;9(9):589-597. doi: 10.1177/1758834017719829. Epub 2017 Jul 24. Review.

11.

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.

J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20. Review.

PMID:
29053400
12.

Aligning digital CD8+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma.

Conde E, Caminoa A, Dominguez C, Calles A, Walter S, Angulo B, Sánchez E, Alonso M, Jimenez L, Madrigal L, Hernando F, Sanz-Ortega J, Jimenez B, Garrido P, Paz-Ares L, de Castro J, Hernandez S, Lopez-Rios F.

Histopathology. 2018 Jan;72(2):270-284. doi: 10.1111/his.13346. Epub 2017 Nov 3.

PMID:
28815764
13.

Retraction: Oncogenic activity of Cdc6 through repression of the INK4/ARF locus.

Gonzalez S, Klatt P, Delgado S, Conde E, Lopez-Rios F, Sanchez-Cespedes M, Mendez J, Antequera F, Serrano M.

Nature. 2017 Jul 12;547(7662):246. doi: 10.1038/nature23287.

PMID:
28703201
14.

Biomarkers in pancreatic ductal adenocarcinoma.

Gallego J, López C, Pazo-Cid R, López-Ríos F, Carrato A.

Clin Transl Oncol. 2017 Dec;19(12):1430-1437. doi: 10.1007/s12094-017-1691-5. Epub 2017 Jun 14. Review.

PMID:
28616721
15.

Biological therapies in nonsmall cell lung cancer.

Zugazagoitia J, Molina-Pinelo S, Lopez-Rios F, Paz-Ares L.

Eur Respir J. 2017 Mar 2;49(3). pii: 1601520. doi: 10.1183/13993003.01520-2016. Print 2017 Mar. Review.

16.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

17.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A.

Clin Transl Oncol. 2017 Jun;19(6):667-681. doi: 10.1007/s12094-016-1594-x. Epub 2016 Dec 19.

18.

A consensus statement on the gender perspective in lung cancer.

Isla D, Majem M, Viñolas N, Artal A, Blasco A, Felip E, Garrido P, Remón J, Baquedano M, Borrás JM, Die Trill M, García-Campelo R, Juan O, León C, Lianes P, López-Ríos F, Molins L, Planchuelo MÁ, Cobo M, Paz-Ares L, Trigo JM, de Castro J.

Clin Transl Oncol. 2017 May;19(5):527-535. doi: 10.1007/s12094-016-1578-x. Epub 2016 Nov 24. Review.

PMID:
27885542
19.

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.

Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M.

Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311.

20.

Testing for ROS1 in non-small cell lung cancer: a review with recommendations.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, López-Ríos F, Marchetti A, Öz B, Pauwels P, Penault-Llorca F, Rossi G, Ryška A, Thunnissen E.

Virchows Arch. 2016 Nov;469(5):489-503. Epub 2016 Aug 17. Review.

21.

Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?

Kerr KM, López-Ríos F.

Ann Oncol. 2016 Sep;27 Suppl 3:iii16-iii24. doi: 10.1093/annonc/mdw302. Review.

PMID:
27573752
22.

Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas.

Conde E, Hernandez S, Prieto M, Martinez R, Lopez-Rios F.

Expert Rev Mol Diagn. 2016 Jun;16(6):707-13. doi: 10.1586/14737159.2016.1172963. Epub 2016 Apr 15. Review.

PMID:
27031368
23.

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group.

Dietel M, Bubendorf L, Dingemans AM, Dooms C, Elmberger G, García RC, Kerr KM, Lim E, López-Ríos F, Thunnissen E, Van Schil PE, von Laffert M.

Thorax. 2016 Feb;71(2):177-84. doi: 10.1136/thoraxjnl-2014-206677. Epub 2015 Nov 3. Review.

24.

SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.

Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD.

Clin Cancer Res. 2015 Nov 1;21(21):4811-8. doi: 10.1158/1078-0432.CCR-14-3222. Epub 2015 Jul 13. Erratum in: Clin Cancer Res. 2016 Dec 15;22(24):6302.

25.

The anaplastic lymphoma kinase testing conundrum.

Conde E, Taniere P, Lopez-Rios F.

Expert Rev Mol Diagn. 2015 Feb;15(2):161-3. doi: 10.1586/14737159.2015.997713. Epub 2015 Jan 12.

PMID:
25579121
26.

Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria.

von Laffert M, Warth A, Penzel R, Schirmacher P, Kerr KM, Elmberger G, Schildhaus HU, Büttner R, Lopez-Rios F, Reu S, Kirchner T, Pauwels P, Specht K, Drecoll E, Höfler H, Aust D, Baretton G, Bubendorf L, Stallmann S, Fisseler-Eckhoff A, Soltermann A, Tischler V, Moch H, Penault-Llorca F, Hager H, Schäper F, Lenze D, Hummel M, Dietel M.

J Thorac Oncol. 2014 Nov;9(11):1685-92. doi: 10.1097/JTO.0000000000000332.

27.

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Felip E, Concha Á, de Castro J, Gómez-Román J, Garrido P, Ramírez J, Isla D, Sanz J, Paz-Ares L, López-Ríos F.

Clin Transl Oncol. 2015 Feb;17(2):103-12. doi: 10.1007/s12094-014-1248-9. Epub 2014 Oct 29. Review.

PMID:
25351175
28.

Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Conde E, Suárez-Gauthier A, Benito A, Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D, de Castro J, Camacho MC, Rodriguez-Abreu D, Abdulkader I, Ramirez J, Reguart N, Salido M, Pijuán L, Arriola E, Sanz J, Folgueras V, Villanueva N, Gómez-Román J, Hidalgo M, López-Ríos F.

PLoS One. 2014 Sep 23;9(9):e107200. doi: 10.1371/journal.pone.0107200. eCollection 2014.

29.

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.

Estévez LG, Suarez-Gauthier A, García E, Miró C, Calvo I, Fernández-Abad M, Herrero M, Marcos M, Márquez C, Lopez Ríos F, Perea S, Hidalgo M.

Breast Cancer Res. 2014 Sep 4;16(4):R76. doi: 10.1186/bcr3695.

30.

Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.

Agulló-Ortuño MT, Díaz-García CV, Agudo-López A, Pérez C, Cortijo A, Paz-Ares L, López-Ríos F, Pozo F, de Castro J, Cortés-Funes H, López Martín JA.

J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1.

PMID:
25081930
31.

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.

Gomez-Martín C, Lopez-Rios F, Aparicio J, Barriuso J, García-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vázquez-Sequeiros E, Lordick F.

Cancer Lett. 2014 Aug 28;351(1):30-40. doi: 10.1016/j.canlet.2014.05.019. Epub 2014 Jun 3. Review.

PMID:
24943493
32.

A new generation of companion diagnostics: cobas BRAF, KRAS and EGFR mutation detection tests.

Angulo B, Lopez-Rios F, Gonzalez D.

Expert Rev Mol Diagn. 2014 Jun;14(5):517-24. doi: 10.1586/14737159.2014.910120. Review.

PMID:
24844134
33.

Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. No abstract available.

34.

Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.

Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M.

Clin Cancer Res. 2014 May 1;20(9):2476-84. doi: 10.1158/1078-0432.CCR-13-3047. Epub 2014 Mar 14.

35.

MicroRNA-dependent regulation of transcription in non-small cell lung cancer.

Molina-Pinelo S, Gutiérrez G, Pastor MD, Hergueta M, Moreno-Bueno G, García-Carbonero R, Nogal A, Suárez R, Salinas A, Pozo-Rodríguez F, Lopez-Rios F, Agulló-Ortuño MT, Ferrer I, Perpiñá A, Palacios J, Carnero A, Paz-Ares L.

PLoS One. 2014 Mar 13;9(3):e90524. doi: 10.1371/journal.pone.0090524. eCollection 2014.

36.

Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.

Cubillo A, Rodriguez-Pascual J, López-Ríos F, Plaza C, García E, Álvarez R, de Vicente E, Quijano Y, Hernando O, Rubio C, Perea S, Sanchez G, Hidalgo M.

Am J Clin Oncol. 2016 Jun;39(3):236-42. doi: 10.1097/COC.0000000000000045.

PMID:
24517959
37.

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F.

J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14.

PMID:
24127447
38.

Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy.

Gómez Dorronsoro ML, Vera R, Ortega L, Plaza C, Miquel R, García M, Díaz E, Ortiz MR, Pérez J, Hörndler C, Villar C, Antúnez J, Pereira S, López-Rios F, González-Cámpora R.

Clin Transl Oncol. 2014 Mar;16(3):234-42. doi: 10.1007/s12094-013-1104-3. Epub 2013 Sep 10.

PMID:
24019036
39.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1.

40.

Health economics and outcomes research: informing companion diagnostic development, guidelines, adoption and reimbursement.

Lee J, Lopez-Rios F.

Expert Rev Mol Diagn. 2013 Jun;13(5):413-5. doi: 10.1586/erm.13.27. No abstract available.

PMID:
23782247
41.

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.

Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellví J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M.

Int J Cancer. 2013 Aug 15;133(4):898-907. doi: 10.1002/ijc.28090. Epub 2013 Mar 9.

42.

Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Tsai J, Vaks J, Current R, Lawrence HJ, Gonzalez de Castro D.

J Clin Pathol. 2013 May;66(5):381-5. doi: 10.1136/jclinpath-2012-201240. Epub 2013 Feb 5.

43.

The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre.

Conde E, Angulo B, Izquierdo E, Muñoz L, Suárez-Gauthier A, Plaza C, Dominguez N, Torres M, Madrigal L, Rubio-Viqueira B, Belda-Iniesta C, Hidalgo M, López-Ríos F.

Histopathology. 2013 Mar;62(4):609-16. doi: 10.1111/his.12037. Epub 2013 Feb 5.

44.

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers.

Conde E, Angulo B, Izquierdo E, Paz-Ares L, Belda-Iniesta C, Hidalgo M, López-Ríos F.

Clin Transl Oncol. 2013 Jul;15(7):503-8. doi: 10.1007/s12094-012-0983-z. Epub 2013 Jan 29.

45.

Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: pre-approval validation study of the companion diagnostic test for vemurafenib.

Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, Shieh F, Vaks J, Langland R, Lawrence HJ, de Castro DG.

PLoS One. 2013;8(1):e53733. doi: 10.1371/journal.pone.0053733. Epub 2013 Jan 10.

46.

Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test.

Rüschoff J, Kerr KM, Grote HJ, Middel P, von Heydebreck A, Alves VA, Baldus SE, Büttner R, Carvalho L, Fink L, Jochum W, Lo AW, López-Ríos F, Marx A, Molina TJ, Olszewski WT, Rieker RJ, Volante M, Thunnissen E, Wrba F, Celik I, Störkel S.

Arch Pathol Lab Med. 2013 Sep;137(9):1255-61. doi: 10.5858/arpa.2012-0605-OA. Epub 2012 Dec 27.

PMID:
23270410
47.

A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.

Cubillo A, Hernando-Requejo O, García-García E, Rodriguez-Pascual J, De Vicente E, Morelli P, Rubio C, López-Ríos F, Muro A, López U, Prados S, Quijano Y, Hidalgo M.

Am J Clin Oncol. 2014 Apr;37(2):117-21. doi: 10.1097/COC.0b013e31826e0703.

PMID:
23211222
48.

PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Estevez-Garcia P, Castaño A, Martin AC, Lopez-Rios F, Iglesias J, Muñoz-Galván S, Lopez-Calderero I, Molina-Pinelo S, Pastor MD, Carnero A, Paz-Ares L, Garcia-Carbonero R.

BMC Cancer. 2012 Nov 12;12:514. doi: 10.1186/1471-2407-12-514.

49.

A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.

Angulo B, Conde E, Suárez-Gauthier A, Plaza C, Martínez R, Redondo P, Izquierdo E, Rubio-Viqueira B, Paz-Ares L, Hidalgo M, López-Ríos F.

PLoS One. 2012;7(8):e43842. doi: 10.1371/journal.pone.0043842. Epub 2012 Aug 27.

50.

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.

Thunnissen E, Bubendorf L, Dietel M, Elmberger G, Kerr K, Lopez-Rios F, Moch H, Olszewski W, Pauwels P, Penault-Llorca F, Rossi G.

Virchows Arch. 2012 Sep;461(3):245-57. doi: 10.1007/s00428-012-1281-4. Epub 2012 Jul 24. Review.

Supplemental Content

Loading ...
Support Center